Search results
Showing 46 to 60 of 67 results for ulcerative colitis
immunomodulators. Source guidance details Comes from guidance Ulcerative colitis: management Number NG130 Date issued May 2019
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
This guidance has been updated and replaced by NICE guideline NG130.
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)
This evidence summary has been updated and replaced by NICE guideline NG130.
Infliximab for subacute manifestations of ulcerative colitis (TA140)
This guidance has been updated and replaced by NICE technology appraisal guidance 329.
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)
This guidance has been updated and replaced by NICE technology appraisal guidance 329.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.